Blog

 

■ Are three weeks of oral anticoagulation sufficient for safe cardioversion in atrial fibrillation?

S Naydenov, N Runev, E Manov

Medicina (Kaunas) 2021, vol 57 (6): 554

https://www.mdpi.com/1648-9144/57/6/554

 

■ Large-scale screening studies for atrial fibrillation – is it worth the effort?

1. Engdahl, M. Rosenqvist

J Intern Med.2021, vol 289(4): 474–49

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8048511/

 

■ What clinical trials of ablation for atrial fibrillation tell us – and what they do not

Ram Amuthan, Anne B. Curtis

Heart Rhythm O2. 2021, vol 2(2): 174–186

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8183809/

 

■ Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach?

Natale Daniele Brunetti, Lucia Tricarico, Luisa De Gennaro et al

Int J Cardiol Heart Vasc.2020, vol 29: 100569

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330069/

 

■ Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? A systematic review and meta-analysis

Alireza Sepehri Shamloo, Nikolaos Dagres, Boris Dinov et al

Int J Cardiol Heart Vasc.2019  vol 22: 132–138

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356021/

 

■ Genetics of atrial fibrillation – practical applications for clinical management: if not now, when and how?

Shinwan Kany, Bruno Reissmann, Andreas Metzner et al

Cardiovasc Res.2021, vol 117(7): 1718–1731

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8208749/

 

■ How will genetics inform the clinical care of atrial fibrillation?

1. Benjamin Shoemaker, Rajan L. Shah, Dan M. Roden, Marco V. Perez

Circ Res. 2020 Jun 19; 127(1): 111–127

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8436048/

 

■ Are interactions between epicardial adipose tissue, cardiac fibroblast and cardiac myocytes instrumental in atrial fibrosis and atrial fibrillation?

Anirudh Krishnan, Emily Chilton, Jaishankar Raman et al

Cells.2021, vol 10(9): 2501

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8467050/

 

■ Racial differences in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?

P Badertscher, D Gregg, C F Baicu et al

Heart Rhythm 02 2021, vol 2 (1): 37-45

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8183868/

 

■ Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Blog Internet Médica – www.internetmedica.com.br

Data: novembro 2021

 

■ Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group

Winfried M. Amoaku, Faruque Ghanchi, Clare Bailey, et al

Eye (Lond) 2020, vol 34(Suppl 1): 1–51

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7337227/

 

■ Recent advancement in the medical treatment of diabetic retinal disease

Maja Szymanska, Daanyaal Mahmood, Timothy E. Yap, Maria F. Cordeiro

Int J Mol Sci.2021, vol 22(17): 9441

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8430918/

 

■ Diabetic retinopathy in the aging population: a perspective of pathogenesis and treatment

Sameer P Leley, Thomas A Ciulla, Ashay D Bhatwadekar

Clin Interv Aging.2021;, vol 16: 1367–137

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8289197/

 

■ Diabetes mellitus e suas complicações – uma revisão sistemática e informativa

R M F de Castro, A M N Silva, A K S da Silva et al

Brazilian Jou 2021, vol 4 (1)

https://www.brazilianjournals.com/index.php/BJHR/article/view/24958/19902

 

■ Role of oral antioxidant supplementation in the current management of diabetic retinopathy

Enrique Antonio Alfonso-Muñoz, Raquel Burggraaf-Sánchez de las Matas, Jorge Mataix Boronat et al

Int J Mol Sci.2021, vol 22(8): 4020

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8069935/

 

■ An evidence map of clinical practice guideline recommendations and quality on diabetic retinopathy

Y Sun, T Cai, J Chen et al

Eye (Lond) 2020, vol 34 (11): 1989-2000

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7784673/

 

■ Intravitreal anti-vascular endothelial growth factor agents for the treatment of diabetic retinopathy: a review of the literature

Irini Chatziralli, Anat Loewenstein

Pharmaceutics.2021, vol 13(8): 1137

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8399287/

 

■ The safety of pharmacological and surgical treatment of diabetes in patients with diabetic retinopathy – a review

Wojciech Matuszewski, Angelika Baranowska-Jurkun, Magdalena Maria Stefanowicz-Rutkowska et al

J Clin Med.2021, vol 10(4): 705

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7916896/

 

■ A systematic review of carotenoids in the management of diabetic retinopathy

Drake W. Lem, Dennis L. Gierhart, Pinakin Gunvant Davey

Nutrients.2021, vol 13(7): 2441

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8308772/

 

■ Emerging roles of dylipidemia and hyperglycemia in diabetic retinopathy: molecular mechanisms and clinical perspectives

Hussain Rao, Jonathan A. Jalali, Thomas P. Johnston, Peter Koulen

Front Endocrinol (Lausanne) 2021; vol 12: 620045

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8020813/

 

■ HBA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcomes trials: a meta-analysis and meta-regression

M A Bethel, R Diaz, N Casttellana et al

Diabetes Care 2021, vol 44 (1): 290-296

https://care.diabetesjournals.org/content/44/1/290

 

■ Review of the management of sight-threatening diabetic retinopathy during pregnancy

P P Choo, N Din, N Azmi et al

World J Diabetes 2021, vol 12 (9): 1386-1400

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8472492/

 

■ Celular targets in diabetic retinopathy therapy

M L Rodríguez, I Millán A L Ortega

World J Diabetes 2021, vol12 (9): 1442-1462

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8472497/

 

■ Epigenetic mechanism in type 2 diabetes retinopatht: a systematic review

Agostino Milluzzo, Andrea Maugeri, Martina Barchitta et al

Int J Mol Sci.2021, vol 22(19): 10502

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8509039/

 

■ Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Blog Internet Médica – www.internetmedica.com.br

Data: novembro 2021